Connor, Clark & Lunn Investment Management Ltd. Bristol Myers Squibb CO Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 69,171 shares of BMY stock, worth $4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
69,171
Holding current value
$4 Million
% of portfolio
0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$39.66 - $51.75 $2.74 Million - $3.58 Million
69,171 New
69,171 $3.58 Million
Q1 2024

May 09, 2024
SELL
$47.98 - $54.4 $70.1 Million - $79.5 Million
-1,461,160 Reduced 97.28%
40,873 $2.22 Million
Q4 2023

Feb 09, 2024
BUY
$48.48 - $57.85 $18.1 Million - $21.6 Million
372,669 Added 33.0%
1,502,033 $77.1 Million
Q3 2023

Nov 13, 2023
BUY
$57.89 - $64.73 $63.1 Million - $70.5 Million
1,089,745 Added 2750.56%
1,129,364 $65.5 Million
Q2 2023

Aug 10, 2023
BUY
$63.71 - $70.74 $1.11 Million - $1.23 Million
17,443 Added 78.66%
39,619 $2.53 Million
Q1 2023

May 09, 2023
SELL
$65.71 - $74.53 $30.4 Million - $34.5 Million
-462,302 Reduced 95.42%
22,176 $1.54 Million
Q4 2022

Feb 10, 2023
BUY
$68.48 - $81.09 $31.7 Million - $37.5 Million
463,064 Added 2162.44%
484,478 $34.9 Million
Q3 2022

Nov 10, 2022
SELL
$0.13 - $76.84 $32,050 - $18.9 Million
-246,540 Reduced 92.01%
21,414 $1.52 Million
Q2 2022

Aug 05, 2022
SELL
$72.62 - $79.98 $42.4 Million - $46.7 Million
-584,171 Reduced 68.55%
267,954 $20.6 Million
Q1 2022

May 12, 2022
BUY
$61.48 - $73.72 $7.39 Million - $8.86 Million
120,249 Added 16.43%
852,125 $62.2 Million
Q4 2021

Feb 10, 2022
BUY
$53.63 - $62.52 $36.3 Million - $42.3 Million
677,201 Added 1238.59%
731,876 $45.6 Million
Q3 2021

Nov 12, 2021
BUY
$59.17 - $69.31 $3.24 Million - $3.79 Million
54,675 New
54,675 $3.24 Million
Q4 2020

Feb 16, 2021
SELL
$57.74 - $65.43 $20.6 Million - $23.3 Million
-356,265 Closed
0 $0
Q3 2020

Nov 12, 2020
SELL
$57.43 - $63.64 $24.5 Million - $27.1 Million
-426,395 Reduced 54.48%
356,265 $21.5 Million
Q2 2020

Aug 13, 2020
SELL
$54.82 - $64.09 $2.03 Million - $2.37 Million
-36,990 Reduced 4.51%
782,660 $46 Million
Q1 2020

May 13, 2020
BUY
$46.4 - $67.43 $37.9 Million - $55 Million
815,944 Added 22016.84%
819,650 $45.7 Million
Q4 2019

Feb 12, 2020
BUY
$49.21 - $64.19 $182,372 - $237,888
3,706 New
3,706 $238,000
Q3 2019

Nov 13, 2019
SELL
$42.77 - $50.71 $35.1 Million - $41.6 Million
-819,732 Closed
0 $0
Q2 2019

Aug 07, 2019
BUY
$44.62 - $49.34 $489,704 - $541,506
10,975 Added 1.36%
819,732 $37.2 Million
Q1 2019

May 08, 2019
BUY
$45.12 - $53.8 $8.73 Million - $10.4 Million
193,556 Added 31.46%
808,757 $38.6 Million
Q4 2018

Feb 12, 2019
BUY
$48.76 - $63.23 $4.12 Million - $5.35 Million
84,560 Added 15.94%
615,201 $32 Million
Q3 2018

Nov 13, 2018
SELL
$55.19 - $62.25 $6.01 Million - $6.78 Million
-108,950 Reduced 17.03%
530,641 $32.9 Million
Q2 2018

Aug 02, 2018
BUY
$50.53 - $62.98 $8.58 Million - $10.7 Million
169,875 Added 36.17%
639,591 $35.4 Million
Q1 2018

May 14, 2018
BUY
$59.92 - $68.98 $1.3 Million - $1.5 Million
21,700 Added 4.84%
469,716 $29.7 Million
Q4 2017

Feb 09, 2018
BUY
$59.94 - $65.35 $130,369 - $142,136
2,175 Added 0.49%
448,016 $27.5 Million
Q3 2017

Nov 14, 2017
BUY
$55.23 - $63.74 $17.9 Million - $20.7 Million
324,400 Added 267.13%
445,841 $28.4 Million
Q2 2017

Aug 14, 2017
BUY
N/A
121,441
121,441 $6.77 Million

Others Institutions Holding BMY

# of Institutions
2,536
Shares Held
1.47B
Call Options Held
31.6M
Put Options Held
35M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email